衷心研究 (HEARTFELT)
一项务实、单盲、随机交叉试验,测试自主远程患者外周水肿监测和心力衰竭警报与传统远程患者监测相比的有效性。
This pragmatic randomized crossover trial looks at the effect(s) of using a remote patient monitoring device (Heartfelt device) with health alerts to monitor the development of peripheral edema in patients with heart failure (HF). The hypothesis is that this passive measurement method will lead to better data availability, which in turn will improve patient care and reduce hospitalizations for the management of worsening HF (HF hospitalizations, HFHs) in nonadherent participants with chronic HF. The study objectives are:
-
Primary objective: Establish if the Heartfelt device is safe to use and effective at reducing HFHs.
-
Secondary objectives:
- Establish the effect of the Heartfelt device on data availability compared to existing remote monitoring devices.
- Establish the effect of the Heartfelt device on HF clinical outcomes.
Participants will need to:
- Install the device in their home for at least a year and up to 4 additional years after.
- Reply to remote patient monitoring phone calls to follow the care plans.
研究概览
地位
详细说明
Participants will be recruited through Remote Patient Monitoring Providers (RPMPs) based in the US, using crossover randomization between standard care and Heartfelt device usage with health alerts sent to RPMPs. The RPMPs will follow a protocolized intervention when responding to raised alerts.
The study design is a crossover randomization between:
- Standard care (control), 162 days: The device is installed in the home and captures data but no health alerts are sent, and the RPMP does not receive data from the device. (Health alerts are generated and stored for review at the end of the study period to correlate with health issues which occurred during usual care).
- Standard care + Heartfelt (intervention), 162 days: The device captures data and transmits volume measurements and health alerts to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.
At consent, patients get randomized to an install date over a period from 21 to 60 days following consent, subject to scheduling this at least 14 days after the most recent recorded hospital discharge at the time of consent, or the discharge from their current hospitalization if hospitalized at the time of consent.
Total study length is 366 days (days 0 to 365). There are two 21-day "washout" periods to prevent carryover between study arms. The first washout period extends from day 0-20 inclusive, and the second from day 183-203 inclusive
At the completion of both crossover arms, patients will be offered the opportunity to keep the device for as long as the study remains active (potentially up to an additional 4 years, for those patients recruited early in the study). During this long-term follow-up, the device will be placed in "Intervention" mode, with randomized 100-day periods where the device is switched into "Standard care" mode (control).
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:WH Wilson Tang, MD
- 电话号码:+441223 967250
- 邮箱:usa.trial@hftech.org
研究联系人备份
- 姓名:Amparito Cunningham, MD. MPH.
- 电话号码:6176425062
- 邮箱:amparito@hftech.org
学习地点
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- 主动,不招人
- Baptist Health
-
-
Florida
-
Miami、Florida、美国、33135
- 尚未招聘
- Suncare Medicare Center/Suncare Research Center
-
接触:
- Handy del Sol Bello, MD
- 电话号码:305-489-9090
- 邮箱:a.suncareresearch@gmail.com
-
接触:
- Yudaisy Castro Bermudez, DDM
- 电话号码:(305) 489-9090
- 邮箱:mcastrosuncareresearch@gmail.com
-
首席研究员:
- Mailin Rivero Ortega, MD
-
-
New Jersey
-
Hackensack、New Jersey、美国、07601
- 招聘中
- HealthArc
-
接触:
- Kaitlyn Batch-Monteforte, BSN., RN.
- 电话号码:201-992-5561
- 邮箱:kaitlyn@healtharc.io
-
首席研究员:
- Kaitlyn Batch-Monteforte, BSN., RN.
-
-
Pennsylvania
-
Bala-Cynwyd、Pennsylvania、美国、19004
- 招聘中
- Connect America
-
接触:
- Rosemary Kennedy, PhD,RN,FAAN
- 电话号码:610-715-2786
- 邮箱:rosemary.kennedy@connectamerica.com
-
首席研究员:
- Rosemary Kennedy, PhD,RN,FAAN
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
INCLUSION CRITERIA:
-
Provision of signed and dated informed consent form (wet or digital signature)
-
Male or female, aged 22 to [No maximum age]
-
Diagnosed with Chronic Heart failure at least 2 months prior to randomization
-
Documented history of peripheral edema (edema in feet and lower legs), defined as at least one clinical mention in the medical record indicative of oedema during prior clinical assessment.
-
Evidence of heart failure decompensation or elevated risk of future hospitalization, defined by one or more of the following:
- Hospitalization for heart failure occurring at least once in the past 6 months or at least twice in the past 12 months; OR
- Receipt of intravenous/subcutaneous diuretic therapy for heart failure (inpatient or outpatient setting) occurring at least once in the past 6 months or at least twice in the past 12 months; OR
- Emergency department or urgent care visit for heart failure decompensation, occurring at least once in the past 6 months or at least twice in the past 12 months; OR
- Clinician assessment that the participant is at high risk of heart failure hospitalization within the next 6-12 months, based on documented recent clinical course (e.g. worsening congestion, escalating diuretic requirements, recurrent decompensation, and/or comorbidity burden).
-
Patients who are prescribed diuretics (daily or PRN).
-
Evidence of non-adherence defined by one or more of the following:
-
Participants with ≥180 days of historical monitoring/device data available
- Failure to collect ≥50% of expected days of prescribed home physiological monitoring data (e.g. weight, blood pressure, or other clinician-recommended measurements), assessed over a continuous 180-day period; OR
- Discontinuation from a remote patient monitoring/home monitoring program due to non-adherence; OR
- Failure to adhere to a prescribed home-based therapy/monitoring intervention, supported by device usage data showing <50% of expected days of use over a continuous 180-day period.
-
Participants without ≥180 days of historical monitoring/device data available: Evidence of non-adherence may be demonstrated by low data capture over shorter windows, defined as any of the following :
- ≤2 days of monitoring data recorded for each of the most recent 4 consecutive weeks during which any remote monitoring device was continuously available in the patient's home; OR
- ≤3 days of monitoring data recorded in any consecutive 8 week period period during which any remote monitoring device was continuously available in the patient home; AND/OR
-
Documented non-adherence in the medical record within the last 3 years:
- Historical documentation of persistent medication and/or dietary non-adherence, defined as either a clear statement of ongoing non-adherence or ≥2 documented instances of non-adherence concerns (including dosing and/or timing, where available); OR
- Historical documentation on repeated clinical assessments indicating persistent difficulty adhering to recommended self-management activities (e.g. repeated failure to follow monitoring instructions, incomplete engagement with care plan, or repeated non-attendance at scheduled reviews).
-
For participants not previously enrolled in RPM or without sufficient historical monitoring data, non-adherence will be assessed prospectively using connected scales provided at study initiation. Objective adherence metrics derived from scale usage during the initial monitoring period will be used both to characterise baseline adherence and to support predefined subgroup analyses.
-
Clinical teams/PIs discretion as patients being non-adherent.
-
-
For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 weeks after the end of the study.
-
Patients who are covered by an insurance plan that covers IDE-B costs (e.g. Medicare Part-B), OR written contract signed by the patient, or their provider or payor, stating that they will be liable for any trial-associated costs that Medicare would ordinarily cover if the patient were covered by Medicare.
EXCLUSION CRITERIA
- Participant has bandages to lower limbs every day
- Participant has an amputation of both feet
- Participant is a regular wheelchair user inside their home
- Participant is bed-bound
- Participant is of no fixed abode
- Participant is taking part in a conflicting evaluation/study that could confound the results of this evaluation and/or impact clinical interventions and participant outcomes
- Participant is unable to take diuretics
- Participant is on a regular schedule of dialysis
- Participant has a history of recurrent leg or feet deep vein thrombosis (DVT) (two or more episodes within the last 12 months).
- Participant has a history of recurrent leg or feet cellulitis episodes (two or more episodes within the last 12 months).
- Participant is prescribed diltiazem or verapamil on an ongoing basis.
- Participant is pregnant or is not taking medically approved birth control if of child-bearing potential.
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Standard Care (control)
Device is installed and data is captured but volume measurements and health alerts are not transmitted to the RPMP. |
Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
其他名称:
RPMPs in regular contact with patients and collecting health monitoring data as per their standard operating procedures.
其他名称:
Patients were presented with one or more optional questionnaires (some validated, some bespoke)
其他名称:
|
|
实验性的:Standard Care + Heartfelt (intervention)
Device is installed and data is captured, and volume measurements and health alerts are transmitted to the RPMP for review and potential follow-up (per a pre-specified alert protocol). |
Device installed in the patient's home and capturing foot volume data which are processed in the cloud.
其他名称:
RPMPs in regular contact with patients and collecting health monitoring data as per their standard operating procedures.
其他名称:
Patients were presented with one or more optional questionnaires (some validated, some bespoke)
其他名称:
Volume measurements and health alerts transmitted to the RPMP for review. RPMPs follow a pre-specified alert protocol, potentially following up with the patient.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Heart Failure Events (HFEs, a composite of HFH or Worsening HF event without hospitalization (as defined in [1-Abraham])
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to demonstrate whether the device effectively reduces HFHs and urgent HF visits. |
12 months, plus up to 48 months long term follow-up
|
|
Doubling in serum creatinine (sCr) from baseline with at least 2.0mg/dL
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to ensure that increased diuretic treatment following alerts from the device does not lead to significant increase in AKI |
12 months, plus up to 48 months long term follow-up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Difference in data availability (device generated or contemporaneous self-report)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to measure the data availability from the Heartfelt device. One of the key findings from feasibility trials and pilot studies in the UK have demonstrated an increased data availability. Does this study in the US confirm the previous finding? |
12 months, plus up to 48 months long term follow-up
|
|
The date and length (in hours) of hospital admission and re-admissions
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to review the lead time of health alerts, or the lack of health alerts generated prior to hospital admissions. |
12 months, plus up to 48 months long term follow-up
|
|
Cause of hospitalizations (HF or non-HF)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to review the lead time of health alerts, or the lack of health alerts generated prior to hospital admissions. |
12 months, plus up to 48 months long term follow-up
|
|
Date of increase in HF medications when the patient is home or in the community (not the detailed changes whilst on the ward)
大体时间:12 months, plus up to 48 months long term follow-up
|
This may include oral diuretic, IV diuretics and subcutaneous furosemide injections. Used to allow the determination if an outpatient appointment is HF related or not. |
12 months, plus up to 48 months long term follow-up
|
|
Death and cause of death from the clinical record (HF or non-HF as defined in [1-Abraham])
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish if using the device changes HF- or non-HF mortality. |
12 months, plus up to 48 months long term follow-up
|
|
Loss of independence (patient unable to live at home; for example, relocation to a care facility for an indefinite duration)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish if there has been an effect on the ability of the patient to live independently in their home. |
12 months, plus up to 48 months long term follow-up
|
|
Route of admission for hospitalization events (ICU, CCU, or ward admission),and discharge (home, skilled nursing facility and long term care facility).
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission. |
12 months, plus up to 48 months long term follow-up
|
|
Scheduling of care events (scheduled or unscheduled)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission. |
12 months, plus up to 48 months long term follow-up
|
|
The setting of care events (inpatient or outpatient)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish if using the device changes the scheduling and/or setting of care and/or route of admission. |
12 months, plus up to 48 months long term follow-up
|
|
Date and time of health alerts generated by the Heartfelt device
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish the response time to health alerts. |
12 months, plus up to 48 months long term follow-up
|
|
Date, time and method of contact made following reception of a health alert generated by the Heartfelt device
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish the response time to health alerts. |
12 months, plus up to 48 months long term follow-up
|
|
Date and reason for study withdrawal
大体时间:12 months, plus up to 48 months long term follow-up
|
Used alongside the analysis of other right-censoring endpoints. |
12 months, plus up to 48 months long term follow-up
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
NT Pro-BNP or BNP, with date if available in patient records
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to correlate NT Pro-BNP health alert status. |
12 months, plus up to 48 months long term follow-up
|
|
Date and time of health alerts from other monitoring devices
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to correlate health alerts from other medical devices and the Heartfelt device. |
12 months, plus up to 48 months long term follow-up
|
|
Symptoms diary (if available)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish patient usage of symptom diaries. |
12 months, plus up to 48 months long term follow-up
|
|
Questionnaire responses (if available)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to establish patient acceptability of the device. |
12 months, plus up to 48 months long term follow-up
|
|
Dates, types and length of stays in rehab facilities/nursing home/care homes
大体时间:12 months, plus up to 48 months long term follow-up
|
Recorded in hours if <48h and in days if >48h. Proxy used to identify trends in worsening of patient's health/independence/quality of life following participation in various arms of the study. |
12 months, plus up to 48 months long term follow-up
|
|
Dates and times of caregivers' shifts if home healthcare used
大体时间:12 months, plus up to 48 months long term follow-up
|
Proxy used to identify trends in worsening of patient's health/independence/quality of life following participation in various arms of the study. |
12 months, plus up to 48 months long term follow-up
|
|
HFHs in the 12 months prior to installation (as defined in [1-Abraham])
大体时间:Retrospectively, over the 12 months prior to device installation
|
Used to compare HF Hospitalization date before the study as a baseline period and during the study. |
Retrospectively, over the 12 months prior to device installation
|
|
UHFV and other urgent healthcare usage in the 12 months prior to installation
大体时间:Retrospectively, over the 12 months prior to device installation
|
Used to compare Heart Failure Visit numbers before the study as a baseline period and during the study. |
Retrospectively, over the 12 months prior to device installation
|
|
Date and cause of Death
大体时间:12 months
|
Used to supplement data on HF-related death that is collected as a primary endpoint from clinical records of participants, as well as allowing the comparison to non-participants. |
12 months
|
|
Ethnicity
大体时间:At enrollment
|
Used to analyze the other endpoints based on this subgroup. |
At enrollment
|
|
NYHA class
大体时间:At enrollment
|
Used to analyze the other endpoints based on this subgroup. |
At enrollment
|
|
Ejection fraction
大体时间:At enrollment
|
Used to analyze the other endpoints based on this subgroup. |
At enrollment
|
|
Comorbidities
大体时间:At enrollment
|
Used to analyze the other endpoints based on this subgroup. |
At enrollment
|
|
Date, prescription fulfillment and any modifications to dosage of HF medications (if available)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to get an indication of medication adherence. |
12 months, plus up to 48 months long term follow-up
|
|
Optimal medical therapy score (if available)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to get an indication of medication adherence. |
12 months, plus up to 48 months long term follow-up
|
|
Presence of edema reported by clinicians during the clinical encounter (including grading of edema if available)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to validate the device's determination of edema status. |
12 months, plus up to 48 months long term follow-up
|
|
Data availability (device generated or contemporaneous self-report) in the 6 months prior to screening.
大体时间:Retrospectively, over the 6 months prior to screening
|
Used to analyze the other endpoints based on this subgroup. |
Retrospectively, over the 6 months prior to screening
|
|
Device-related complications
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to ensure that any device-related complications that occur after the main 12 months of the study are captured. |
12 months, plus up to 48 months long term follow-up
|
|
Date, time, reason and means of contact made with patients by RPMPs not due to Heartfelt health alerts (e.g. phone triage/counseling, repeat labs, etc)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to determine if any significant changes in outcomes might be due to increases in patient contacts overall. |
12 months, plus up to 48 months long term follow-up
|
|
Tobacco consumption
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup. |
12 months, plus up to 48 months long term follow-up
|
|
Alcohol consumption
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup. |
12 months, plus up to 48 months long term follow-up
|
|
Cannabis consumption
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup. |
12 months, plus up to 48 months long term follow-up
|
|
Other recreational drug(s) consumption
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to determine if any significant changes in outcomes might be due to lifestyle choices and to analyze the other endpoints based on this subgroup. |
12 months, plus up to 48 months long term follow-up
|
|
Cause of hospitalizations (ICD-10-CM codes)
大体时间:12 months, plus up to 48 months long term follow-up
|
Used to determine if a correlation could be identified between treatment effect and type of hospital stays; as well as sensitivity and specificity of the alert analysis. |
12 months, plus up to 48 months long term follow-up
|
合作者和调查者
调查人员
- 学习椅:WH Wilson Tang, MD、Cleveland Clinic, USA
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 55241
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Data collected for this study will be analyzed and stored by the Sponsor. After the study is completed, the de-identified, archived data will be transmitted to and stored by the Sponsor, for use by other researchers including those outside of the study. Permission to transmit data to the Sponsor will be included in the informed consent.
To further reduce the risk of patient identification, we will not associate patients with a named RPMP, we will instead use a site ID for each RPMP.
During the conduct of the study, an individual participant can choose to withdraw consent to have their de-identified data stored for future research. However, withdrawal of consent with regard to data storage may not be possible after the study is completed.
When the study is completed, access to study de-identified data will be provided through the Sponsor.
IPD 共享时间框架
6 months after publication
IPD 共享访问标准
Contact the Sponsor
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.